E. Riechers

Rapid improvement of disease impact in patients with rheumatoid arthritis treated with upadacitinib: Results from a prospective real-world study

Torsten Witte, Uta Kiltz, E. Riechers, Daniela Adolf et autres

Introduction: The SELECT clinical trial program demonstrated upadacitinib to be an effective treatment for RA with an acceptable safety profile [ref:1], [ref:2], [ref:3], [ref:4], [ref:5], [ref:6]. Methods: UPwArds was a post-marketing observational [for full text, please go to the a.m. URL]

de, nl (code pays fourni par la source)

ABS0365 GLUCOCORTICOID-SPARING EFFECT OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS; POST-HOC ANALYSIS FROM THE NON-INTERVENTIONAL STUDY UPWARDS

Torsten Witte, Uta Kiltz, E. Riechers, Daniela Adolf et autres

Background: In clinical practice, continuous use of glucocorticoids (GCs) is common in patients with rheumatoid arthritis (RA) [1, 2]. According to EULAR guidelines, GCs are only recommended for short-term use during treatment initiation with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and should …

de (code pays fourni par la source)

POS0199 HOW DOES AGE AFFECT THE SAFETY PROFILE IN SPONDYLOARTHRITIS PATIENTS TREATED WITH SECUKINUMAB IN REAL WORLD? DATA FROM THE GERMAN AQUILA STUDY

J. Brandt-Juergens, E. Riechers, K. Gente, Stefan Bär et autres

de (code pays fourni par la source)

AB0404 REAL WORLD DATA ON THE EFFECTIVENESS OF SECUKINUMAB ON JOINTS, PAIN, AND DISEASE ACTIVITY IN PSORIATIC ARTHRITIS PATIENTS – RESULTS FROM THE GERMAN AQUILA STUDY

Uta Kiltz, E. Riechers, Karolina Gente, Stefan Bär et autres

AB0510 UNVEILING THE REAL-WORLD IMPACT OF UPADACITINIB – DOES CLINICAL REMISSION MIRROR THE PATIENT’S PERSPECTIVE ON RHEUMATOID ARTHRITIS?

Torsten Witte, Uta Kiltz, Florian Haas, E. Riechers et autres

de (code pays fourni par la source)

The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study

Torsten Witte, Uta Kiltz, Florian Haas, E. Riechers et autres

OBJECTIVES: We investigated whether the effectiveness of upadacitinib in rheumatoid arthritis (RA) treatment is affected by baseline CRP levels in a real-world setting. METHODS: UPwArds was a prospective, non-interventional study. Patients had moderate-to-severe RA and an inadequate response or intolerance to ≥1 …

de (code pays fourni par la source)

POS0841 EFFECTIVENESS AND SAFETY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR TNF-THERAPY IN GERMANY. FINAL RESULTS FROM A POST-MARKETING OBSERVATIONAL STUDY

Torsten Witte, Uta Kiltz, F. Haas, E. Riechers et autres

de (code pays fourni par la source)

POS0684 IS UPADACITINIB CAPABLE OF IMPROVING PATIENT-REPORTED OUTCOMES OF RHEUMATOID ARTHRITIS IN A REAL-WORLD SETTING? RESULTS FROM THE POST-MARKETING OBSERVATIONAL UPwArds STUDY

T. Witte, Uta Kiltz, F. Haas, E. Riechers et autres

de (code pays fourni par la source)

POS1013 HOW DOES BODY MASS INDEX AFFECT SECUKINUMAB TREATMENT OUTCOMES AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY

Uta Kiltz, J. Brandt-Juergens, P. Kästner, E. Riechers et autres

de (code pays fourni par la source)

AB0255 BASELINE CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB IN GERMAN REAL-WORLD PRACTICE: RESULTS FROM THE POST-MARKETING OBSERVATIONAL UPwArds STUDY

Torsten Witte, Uta Kiltz, Felix Haas, E. Riechers et autres

de, be, jp, us, gb, fr, in, kr, mx (code pays fourni par la source)

POS1023 HOW DOES GENDER AFFECT SECUKINUMAB TREATMENT OUTCOMES AND RETENTION RATES IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY

Uta Kiltz, J. Brandt-Juergens, Peter Kästner, E. Riechers et autres

de (code pays fourni par la source)

POS0899 HOW DOES GENDER AFFECT SECUKINUMAB TREATMENT OUTCOMES AND RETENTION RATES IN PATIENTS WITH ANKYLOSING SPONDYLITIS? - REAL WORLD DATA FROM THE GERMAN AQUILA STUDY

Uta Kiltz, J. Brandt-Juergens, Peter Kästner, E. Riechers et autres

de (code pays fourni par la source)